U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168083) titled 'Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression' on Aug. 31.
Brief Summary: Ovarian clear cell carcinoma (OCCC) is a relatively rare but highly malignant epithelial ovarian cancer, accounting for 5%-10% of all ovarian cancers. The incidence of this tumor has significant racial disparity, with the highest incidence in Asians, accounting for 25% of ovarian cancer patients, while in European and American ovarian cancer patients, it only accounts for 4.8%. Due to the unique biological behavior of OCCC, it responds poorly to traditional platinum-based chemotherapy regimens, and the prognosis of p...